Genzyme reported that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compound produced a meaningful impact on key clinical manifestations of Gaucher disease.  The results highlight the potential of this compound to become an innovative treatment option for Gaucher disease. More›

Isis Pharmaceuticals, Inc. and Genzyme Corp. announced today that the FDA has provided guidance regarding approval requirements for mipomersen. More›

Genzyme Corp. announced today that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in China. More›